Home » Stocks » ALKS

Alkermes PLC (ALKS)

Stock Price: $19.04 USD -0.40 (-2.06%)
Updated Feb 26, 2021 4:00 PM EST - Market closed
Market Cap 3.03B
Revenue (ttm) 1.04B
Net Income (ttm) -110.86M
Shares Out 158.80M
EPS (ttm) -0.70
PE Ratio n/a
Forward PE 39.68
Dividend n/a
Dividend Yield n/a
Trading Day February 26
Last Price $19.04
Previous Close $19.44
Change ($) -0.40
Change (%) -2.06%
Day's Open 19.46
Day's Range 18.52 - 19.91
Day's Volume 1,719,780
52-Week Range 11.98 - 23.92

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Zacks Investment Research - 2 weeks ago

Alkermes (ALKS) beats both earnings and sales estimates in the fourth quarter of 2020.

The Motley Fool - 2 weeks ago

The biotech posted a big year-over-year sales decline. But there was a good reason for it.

Zacks Investment Research - 2 weeks ago

Alkermes (ALKS) delivered earnings and revenue surprises of 42.86% and 4.28%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 3 weeks ago

DUBLIN, Feb. 4, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. GMT) on Thursday, Feb. 11, 2021 to discuss the ...

PRNewsWire - 1 month ago

DUBLIN, Jan. 6, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that its Chief Executive Officer, Richard Pops, will provide a corporate overview and update at the 39th Annual...

Forbes - 1 month ago

Our theme of Out Of Favor Health Care Stocks includes health care names that have witnessed strong growth and improving fundamentals over the last few years but have still underperformed over ...

Other stocks mentioned: BMRN, IONS
PRNewsWire - 2 months ago

DUBLIN, Dec. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has acknowledged receipt of the company's New Drug Applicatio...

Zacks Investment Research - 2 months ago

Alkermes (ALKS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks Investment Research - 2 months ago

Alkermes' (ALKS) Value Enhancement Plan is set to drive growth, improve operational and financial performance, as well as enhance shareholder value.

The Motley Fool - 2 months ago

The biotech has a plan to increase profitability.

PRNewsWire - 2 months ago

DUBLIN, Dec. 10, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced a Value Enhancement Plan, or the Plan, designed to drive growth, improve operational and financial performance...

Zacks Investment Research - 3 months ago

Alkermes (ALKS) gets a CRL by the FDA for ALKS 3831 for the treatment of adults with schizophrenia and bipolar I disorder.

PRNewsWire - 3 months ago

DUBLIN, Nov. 17, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding i...

Seeking Alpha - 3 months ago

Alkermes plc (ALKS) CEO Richard Pops on Q3 2020 Results - Earnings Call Transcript

Zacks Investment Research - 4 months ago

Alkermes (ALKS) beats earnings and sales estimates in the third quarter of 2020. The company also raises 2020 guidance.

PRNewsWire - 4 months ago

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announces that the conference call to discuss the company's third quarter financial results is rescheduled due to technical di...

Zacks Investment Research - 4 months ago

Alkermes (ALKS) delivered earnings and revenue surprises of 2700.00% and 11.00%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 4 months ago

DUBLIN, Oct. 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2020 and provided updated financial expectations for full-year 2020....

PRNewsWire - 4 months ago

DUBLIN, Oct. 22, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (12:00 p.m. GMT) on Thursday, Oct. 29, 2020 to discuss th...

Zacks Investment Research - 4 months ago

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Forbes - 4 months ago

Our indicative theme of Out Of Favor Healthcare Stocks is down by about -10% year-to-date, versus the S&P 500 which is up by about 8% year-to-date. This theme includes healthcare and pharma co...

Other stocks mentioned: NBIX, ACAD, ARWR, BMRN, IONS
Zacks Investment Research - 4 months ago

Alkermes (ALKS) gets positive votes from the FDA Advisory Committee for ALKS 3831, which is being evaluated for the treatment of adults with schizophrenia and bipolar I disorder.

Investors Business Daily - 4 months ago

An FDA joint committee's favorable votes on an Alkermes drug candidate to treat bipolar I and schizophrenia came just weeks ahead of an expected key FDA decision and sent ALKS stock rising. Th...

PRNewsWire - 4 months ago

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced positive voting outcomes from the joint meeting of the Psychopharmacologic Drugs Advisory Committee and the Dru...

PRNewsWire - 4 months ago

DUBLIN, Oct. 9, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that Nasdaq has temporarily halted trading of the company's ordinary shares. The joint meeting of the Psychopha...

PRNewsWire - 4 months ago

DUBLIN, Oct. 7, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that the U.S. Food and Drug Administration (FDA) has posted on its website briefing documents for the Oct. 9, 2...

Zacks Investment Research - 5 months ago

LGND vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: LGND
PRNewsWire - 5 months ago

DUBLIN, Sept. 18, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today presented new clinical data from ARTISTRY-1, an ongoing phase 1/2 study evaluating Alkermes' investigational engineered...

PRNewsWire - 5 months ago

DUBLIN, Sept. 14, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the presentation of new real-world outcomes research and clinical data related to its psychiatry portfolio at...

PRNewsWire - 5 months ago

DUBLIN, Sept. 8, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will present new clinical data related to ALKS 4230, its investigational engineered interleukin-2 (IL-...

Zacks Investment Research - 6 months ago

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research - 6 months ago

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ANIK
PRNewsWire - 6 months ago

DUBLIN, Aug. 21, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that a joint meeting of the U.S.

Zacks Investment Research - 6 months ago

Alkermes (ALKS) initiates phase II ARTISTRY-3 study to evaluate the clinical and immunologic effects of ALKS 4230 monotherapy in patients with advanced solid tumors.

PRNewsWire - 6 months ago

DUBLIN, Aug. 19, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the initiation of ARTISTRY-3, a new phase 2 study to evaluate the clinical and immunologic effects of ALKS 423...

Zacks Investment Research - 6 months ago

ANIK vs. ALKS: Which Stock Is the Better Value Option?

Other stocks mentioned: ANIK
Zacks Investment Research - 7 months ago

Alkermes' (ALKS) earnings decline year over year in the second quarter of 2020.

Seeking Alpha - 7 months ago

Alkermes plc (ALKS) CEO Richard Pops on Q2 2020 Results - Earnings Call Transcript

Zacks Investment Research - 7 months ago

Alkermes (ALKS) delivered earnings and revenue surprises of 700.00% and 3.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Benzinga - 7 months ago

Shares of Alkermes (NASDAQ:ALKS) rose 2.5% in pre-market trading after the company reported Q2 results.

PRNewsWire - 7 months ago

DUBLIN, July 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2020 and provided updated financial expectations for full-year 2020...

Zacks Investment Research - 7 months ago

Alkermes (ALKS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Investment Research - 7 months ago

Alkermes (ALKS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 8 months ago

Investors need to pay close attention to Alkermes (ALKS) stock based on the movements in the options market lately.

PRNewsWire - 8 months ago

DUBLIN, June 29, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that it will begin accepting applications for its annual Alkermes Pathways Research Awards® program on July 1,...

PRNewsWire - 8 months ago

DUBLIN, June 24, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced that 10 nonprofit organizations have been awarded grants from the company's COVID-19 Relief Fund, a special ed...

Zacks Investment Research - 8 months ago

Alkermes (ALKS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

PRNewsWire - 8 months ago

DUBLIN, June 4, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a fireside chat at the 41st Annual Goldman Sachs Global Healthcare Conferen...

Zacks Investment Research - 9 months ago

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock?

PRNewsWire - 9 months ago

DUBLIN, May 27, 2020 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced plans to present new research from its schizophrenia portfolio at the American Society of Clinical Psychopharma...

About ALKS

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. Its marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizop... [Read more...]

Industry
Biotechnology
IPO Date
Jul 16, 1991
CEO
Richard F. Pops
Employees
2,245
Stock Exchange
NASDAQ
Ticker Symbol
ALKS
Full Company Profile

Financial Performance

In 2020, Alkermes's revenue was $1.04 billion, a decrease of -11.29% compared to the previous year's $1.17 billion. Losses were -$110.86 million, -43.62% less than in 2019.

Financial Statements

Analyst Forecasts

According to 12 analysts, the average rating for Alkermes stock is "Hold." The 12-month stock price forecast is 21.89, which is an increase of 14.97% from the latest price.

Price Target
$21.89
(14.97% upside)
Analyst Consensus: Hold